header logo image


Page 871«..1020..870871872873..880890..»

What will the world look like in 50 years? – Quartz

October 18th, 2019 3:46 am

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

To define the characteristics of those companies: They will demonstrate emotional intelligence, flexibility, and the ability to adapt to complex, quickly-shifting conditions, work forces, and social movements. The companies that develop innovative products and services designed to protect people from climate impacts (sea-level rise, extreme heat, disaster) will prosper as well. Examples are companies that make cooling vests for outdoor workers, police officers, and firefighters; flood-response companies; design firms that build resilient structures capable of floating or adapting to rising waters; even private extraction companies like those being used by oil and gas entities to extract personnel from harmful situations like political conflicts, violence, or natural disasters.Further, companies with a majority of women on their boards and executive teams will outperform competitors and lead in their industry. In fact, I would venture that the numbers of men will flip to a women-led majority in most everything in the next 50 years.

Finally, given the increase in both the types of risk and the size of risk exposures such as hurricane, drought, extreme heat, and floods, property and casualty industry will finally transform. Along with reinsurance companies, they will offer individual policies that pay quickly based on a metric such as wind speed or sustained temperature.

More:
What will the world look like in 50 years? - Quartz

Read More...

Marc Thurner Launches mimiX Biotherapeutics to Bioprint in the OR Using Sound – 3DPrint.com

October 18th, 2019 3:46 am

The biofabrication race is on. Scientists around the world are competing and the rise of biotechnological commercial players has diversified the field, moving fast to keep up with high expectations from scientists, healthcare providers and pharmaceutical companies eager to take the research to clinical therapy. But this is no easy transition, and even though bioprinting has moved the field forward, it is not as close to patients as everyone hopes it would be. One new company is now bringing a different message, one of possibility and hope that could pave the way for the future of healthcare.

Newly launched mimiX biotherapeutics is developing the next generation of biofabrication solutions to provide Point-of-Care tissue engineering for regenerative, personalized and precision medicine. Founded by Marc Thurner, who just this year left his previous creation regenHU and is now beginning a new chapter in his life, the startup will commercialize a new bioprocessing technology called Sound Induced Morphogenesis (SIM). Off to a new start, Thurnernow the CEO of mimiX biotherapeuticsspoke with 3DPrint.com about the scientific tool he expects could revolutionize regenerative medicine and diagnostics, and which he expects to launch commercially by next summer.

Could we accelerate the biofabrication revolution in the healthcare industry? wondered Thurner back in June.

This is a big question and one which he believes to have found the answer.

Just after I left regenHU, I began touring the countryside with my family. But I quickly went from a camping experience to a new tech venture. Tiziano Serra (the inventor of 3D-SIM technology) came to see me claiming he had an interesting technology in the field of biofabrication. After spending a week looking over some of the amazing scientific results and data he had developed throughout the last six years I decided this was an opportunity I couldnt miss, revealed Thurner. At the time, I realized that the technology most of the bioprinting companies have, which are based on conventional extrusion systems, are a great tool for scientific research but will probably never make the translation into the clinical environment, he revealed.

Marc Thurner

Instead, mimiX biotherapeutics technology has already demonstrated with scientific evidence that it offers tissue engineering strategies to overcome todays obstacles, for example, the creation of dense networks of cell suitable for micro vascularization.

According to Thurner, bioprinting using conventional dispensing systems is good for science but much too complicated for clinical use due to several critical hurdles including scalability, affordability, manufacturing, and because they entail complicated and labor-intensive processes.

He also claims that the current cell therapy available is costly and time-consuming since patients own biopsies are sent to labs where cells are isolated and amplified to create artificial tissue using 3D printing (or other more conventional methods) so that they can weeks later be transplanted back into the patient. It just takes too long.

It seems clear that we need to overcome this rudimentary process which is not stable and a logistical nightmare. Instead, mimiX biotherapeutics opens the door to manufacturing patient-specific tissues directly in the operating room (OR), enhancing patients autologous biological materials, for their own treatment. So, we see an opportunity to reduce the cost of the tissue engineering procedure. Moreover, we hope that in the future, most medical practitioners will be able to use the patients own biological material to process it directly in the OR without the need of any specific expertise in engineering or robotic tools required by typical bioprinters.

Delivering their technology to the clinical environment is the ultimate goal for the startup, which is headquartered in Neuchtel, Switzerland. Thurner hopes that one day every hospital will have a 3D-SIM system in the OR, to enhance the biomaterial that they obtain from the patient, and create tissue that is ready to be implanted within a few minutes.

Thurner went on to say that this could be possible within a timeframe of 10 years because we are simplifying the process and because the materials dont have to go out of the OR. This means that beyond patient care, we are also offering a solution to one of the biggest problems the healthcare industry has: extremely high costs.

Tiziano Serra

The 3D-SIM technology behind mimiX biotherapeutics is nearly a decade old. It was developed by Tiziano Serra, a Research Scientist at the AO Research Institute in Davos, Switzerland, with the objective of creating well-defined biological patterns that self-assemble into functional tissues using sound waves. A process Serra has poetically defined as orchestrating biology. The company states that SIM is a cell and biologics patterning process to create a 3D biological template in which cells induce morphogenesis through a self-assembly mechanism. SIM technology offers a highly efficient strategy creating dense and organized cell patterns.

The beauty behind SIM is that Serra began exploring its potential many years ago and already understands which type of patterns induce different types of tissue engineering strategies. Our current focus is on micro vascularization, which is the big bottleneck in regenerative medicine.

Our universe is immersed in waves, and mimiX biotherapeutics machines transmit them. A proprietary Labware is first placed on a type of speaker and depending on the sound emitted, the waves that are generated transmit energy to the labware and the cell-cultured media. The cells will then be patterned in different forms, such as circular, square, star shape or in agglomerates to trigger a self-assembly process. The company plans to deliver its novel instrument as a scientific tool next year for the research community, allowing them to explore the potential of what they could achieve when switching from conventional bioprinting to SIM. The small device fits any biosafety cabinet, and Thurner hopes that it will exponentially trigger the intellectual property behind the technology.

Marc Thurner

The company is driven by experienced healthcare, life science managers and scientists and benefits from cooperation with the AO Foundation, a nonprofit organization dedicated to improving the care of people with musculoskeletal injuries and their sequels through research, development, education and quality assurance.

Thurner has already begun setting up strategic partnerships to move forward with research and development, clinical trials, and luring strategic investors to join the venture. He is already preparing for a Series A round of financing to go to market with his prototype and start a clinical journey.

I am convinced we need to work with an open innovation mindset because the field of biofabrication is so versatile. To enable a revolution we need to bring together our expertise in hardware and software, along with cell therapy, clinical and healthcare knowledge. Even more so, our device will be an ideal lab instrument with the potential to be used in many fields, from biotechnology to drug discovery, concluded the expert.

Read more:
Marc Thurner Launches mimiX Biotherapeutics to Bioprint in the OR Using Sound - 3DPrint.com

Read More...

Medtec China 2019 successfully rounds off; upgrading to two pavilions in 2020 to power innovative development of China’s medical device industry -…

October 18th, 2019 3:46 am

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Medtec China 2019, organized by Informa Markets, was successfully held at Shanghai World Expo Exhibition & Convention Center. It brought together 436 exhibitors from 25 countries and regions, including 150 first-time exhibitors; international exhibitors accounting for 56% of the turnout. The exhibition handled 28,057 visitors over three days, mainly professionals of R&D / Technology, Production / Manufacturing, Purchasing, Quality, Regulatory Affairs, and Senior Management from 41 countries and regions.

Industry leaders gather at a Medtec China that provides wide choice for procurement

Medtec China brings together and continues to attract leading medical device manufacturers from home and abroad, to exhibit a great many high-quality innovative technologies and products for the audience, thereby meeting the ever-increasing needs in the medical market.

Tekni - Plex, Suzhou Bank Valley, Baoji Xinuo, DuPont and other material suppliers exhibited Cellene thermoplastic elastomeric particles, medical absorbable biodegradable polymer materials, medical titanium, and the new packaging material Tyvek 40L; Delta Precision, Shanghai Y&L, Gowin Mold, and other enterprises exhibited high-precision and micro-machinery parts, holistic processing and manufacturing systems, and hot runner systems; JoyMed Technology and JCBIO are committed to providing a full range of commissioned product development, clinical, registration and OEM services for small and medium medical device enterprises and clinical institutions around the world. Medical automation device providers, such as Mikron, Team Technik and KAHLE Automation SRL, provide reliable assembly and testing lines for complex products, including POC diagnostic equipment, self-service pen injectors, dialysis filters, inhalers, infusion apparatus, insulin pens, pre-filled syringe, safe indwelling needles, and infusion tubes.

Conferences and forums following the industry focus, full house onsite

Chinese Regulatory Updates and Compliance, the 7th IIMD China Summit, Risk Management of Medical Product Life Cycle, MDR's MDSAP, and MDSAP&QSIT inspection all took place during Medtec to heightened interest. Lin Feng (Director, Medical Device Registry at Shanghai Food & Drug Administration), Feng Xiaoming (Deputy Director, National Institutes for Food and Drug Control (NIFDC) Biomaterials and Tissue Engineering Office), Xi Tingfei (Director of the Medical Device Inspection Center of the China National Institutes for Food and Drug Control), Shao Linyun (Deputy Director of the Central R&D Management Department of Shenzhen Mindray), William Sutton (Assistant Director in the Office of International Programs (OIP) at the United States Food and Drug Administration (FDA) China Office), and other authoritative speakers appeared to present speeches.

Medtec China this year continued to introduce the technology development forum on new medical dressings. Qin Yimin (Director of State Key Laboratory of Bioactive Seaweed Substances) was invited to introduce the properties and applications of silver-containing wound dressings, and Hu Fang (Board Chairman, Bestlife Regenerative Medicine) shared their insights on the selection and use of raw materials in the development and design of new high-end medical dressings.

Overall, there were 15 keynote forums covering 65 sessions of lectures; 53 invited speakers appeared to speak and share; and more than 1,500 industry representatives participated in the onsite events.

Medtec China 2020 will be held againfrom September 1416, 2020. High-quality brand suppliers from nearly 25 countries around the world will offer design, raw materials, precision parts, manufacturing equipment, processing technology, contract customization, testing and certification, policies and regulations, market consulting and other services required for product development, production and registration. It is expected to be attended by more than 30,000 visitors. A wealth of onsite events will offer premium opportunities for visiting and learning. For more information, please visit http://www.medtecchina.com.

Contact Us:Carina LiTel: +86-10-5730-6163E-mail: carina.li@ubm.comMedtec China Organization Committee

View original content to download multimedia:http://www.prnewswire.com/news-releases/medtec-china-2019-successfully-rounds-off-upgrading-to-two-pavilions-in-2020-to-power-innovative-development-of-chinas-medical-device-industry-300939535.html

SOURCE Medtec China

Read the original post:
Medtec China 2019 successfully rounds off; upgrading to two pavilions in 2020 to power innovative development of China's medical device industry -...

Read More...

What the Hippo pathway in cardiac fibroblasts reveals about heart function – Baylor College of Medicine News

October 18th, 2019 3:46 am

Heart failure remains the leading cause of mortality in the U.S. During a heart attack, blood stops flowing into the heart. Without oxygen, part of the heart muscle dies. The heart muscle does not regenerate, instead it replaces dead tissue with a scar made from cells called fibroblasts. If there is too much scarring, the heart progressively weakens. A large proportion of people who had a severe heart attack will develop heat failure and scarring in the heart.

One of the interests of my lab is to develop ways to heal heart muscle by studying cellular pathways involved in heart development and regeneration, said Dr. James F. Martin, professor and Vivian L. Smith Chair in Regenerative Medicine at Baylor College of Medicine and director of the Cardiomyocyte Renewal Lab at the Texas Heart Institute.

In previous studies, Martin and his colleagues discovered that inactivating the Hippo signaling pathway in adult murine hearts triggered cardiac muscle cell regeneration after heart attack. These findings raised hope for the development of promising heart failure therapies involving the Hippo pathway.

In the current study, Martin and his colleagues further investigated the Hippo pathway in the adult murine heart, this time focusing on its role in cardiac fibroblasts, non-muscle cells that are closely associated with cardiac muscle cells. The researchers conducted a number of basic studies, including single cell sequencing experiments that provided a high level of resolution to their analyses.

We inactivated the Hippo pathway in resting adult hearts that did not have any injury and observed that the fibroblasts became activated they proliferated and developed into myofibroblasts, a major cell type that appears in heart tissues after an injury, Martin said.

Mouse hearts with a deficient Hippo pathway in cardiac fibroblasts spontaneously developed cardiac fibrosis, even without injury, which resulted in severe heart dysfunction, said co-first author Dr. Yang Xiao, who was a postdoctoral fellow in the Martin lab during this project. This and other evidence indicated that the Hippo pathway is required to restrain cardiac fibrosis; Hippo is important for maintaining the fibroblasts in their resting state.

In addition, the researchers found that inactivating the Hippo pathway also triggered a molecular cascade resulting in an inflammatory response that was mediated by Yap, a molecule that regulates a number of molecular pathways.

We know that Hippo and Yap work together. Hippo acts like a brake for Yap, so when we took away Hippo, Yap remained active and regulated the expression of important signaling molecules that talk to macrophages and other immune cells luring them into the heart, Martin said.

The researchers believe they have identified important insights into heart function. Their findings inform about the genetic pathways that are important for maintaining the fibroblasts in their resting state.

Find the complete article in the journal Genes & Development.

Other contributors to this work include co-first author Matthew C. Hill, Lele Li, Vaibhav Deshmukh, Thomas J. Martin and Jun Wang. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, the Texas Heart Institute and the University of Texas Health Science Center at Houston.

This study was supported by grants from the National Institutes of Health (DE023177, HL127717, HL130804, HL118761; F31HL136065; K01DE026561); American Heart Association (14SDG19840000), Vivian L. Smith Foundation, State of Texas funding, Fondation LeDucq Transatlantic Networks of Excellence in Cardiovascular Research (14CVD01) Defining the genomic topology of atrial fibrillation. Further support was provided by Intellectual and Developmental Disabilities Research Center grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Mouse Phenotyping Core at Baylor College of Medicine (U54 HG006348).

By Ana Mara Rodrguez, Ph.D.

Original post:
What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News

Read More...

6 Bodily Tissues That Can Be Regenerated Through Nutrition – The Epoch Times

October 18th, 2019 3:46 am

Spontaneous recovery from disease is often painted as superstition but our body can heal itself

It may come as a surprise to some, especially those with conventional medical training, but the default state of the body is one of ceaselessregeneration. Without the flame-like process of continual cell turnover within the bodylife and death ceaselessly intertwinedthe miracle of the human body would not exist

In times of illness, however, regenerative processes are overcome by degenerative ones. This is where medicine may perform its most noble feat, nudging the body back into balance with foods, herbs, nutrients, and healing energies and intentions.

Today, however, drug-based medicine invariably uses chemicals that lackregenerative potential; to the contrary, they commonly interfere with bodily self-renewal in order to suppress the symptoms against which they are applied.

In other words, most medicines attack disease symptoms rather than support the bodys own ability to combat disease.

Over the course of the past few years of trolling MEDLINE (the National Institutes of Healths website produced by the National Library of Medicine), we have collected a series of remarkable studies on a topic considered all but heretical by the conventional medical systemspontaneous remission.

There is actually a broad range of natural compounds with proven nerve-regenerative effects. A 2010 study published in the journalRejuvenation Research, for instance, found a combination of blueberry, green tea and carnosine have neuritogenic (i.e. promoting neuronal regeneration) and stem-cell regenerative effects in an animal model ofneurodegenerative disease.Other researched neuritogenic substances include:

There is another class of nerve-healing substances, known asremyelinatingcompounds, which stimulate the repair of the protective sheath around the axon of the neurons known as myelin. Myelin is often damaged in neurological injury and/or dysfunction, especially autoimmune and vaccine-induceddemyelination disorders.

It should also be noted that evenmusicandfalling in lovehave been studied for possibly stimulating neurogenesis, regeneration and/or repair of neurons, indicating that regenerative medicine does not necessarily require the ingestion of anything; rather, a wide range oftherapeutic actionsmay be employed to improve health and well-being, as well.

[To view the first-hand biomedical citations on these neuritogenic substances, visit GreenMedinfosneuritogenicresearch page online.]

Glycyrrhizin, a compound found within licorice that is also a powerfulanti-SARS virus agent, has also been found to stimulate the regeneration of liver mass and function in the animal model of hepatectomy. Other liver regenerative substances include:

[To view the first-hand biomedical citations, visit GreenMedinfosliver regenerationresearch page on the topic online.]

The medical community has yet to harness the diabetes-reversing potential of natural compounds. Whereas expensive stem cell therapies, islet cell transplants, and an array of synthetic drugs in the developmental pipeline are the focus of billions of dollars of research, annually, our kitchen cupboards and backyards may already contain the long sought-after cure for type 1 diabetes. Nature has a way of providing the things our bodies need.

The following compounds have been demonstrated experimentally to regenerate the insulin-producing beta cells, which are destroyed in insulin-dependent diabetes, and once restored, may (at least in theory) restore the health of the patient to the point where they no longer require insulin replacement.

[To view the first-hand biomedical citations onbeta cell regeneration, visit GreenMedinfos research page on the topic online.]

Secretagogues are substances in the body that cause other substances to be secreted, like sulfonylureas, which triggers insulinrelease. Secretagogues, includingsynthetic secretagogues, can increase the endocrine glands ability to secrete more of a hormone. But even better are substances thattruly regeneratehormones which have degraded. They do this by emitting electrons into potentially carcinogenic transient hormone metabolites. One of these substances isvitamin C.

A powerful electron donor, this vitamin has the ability to contribute electrons to resurrect the form and function of estradiol (estrogen; E2), progesterone, and testosterone, for instance. In tandem withfoods that are able to support the function of glandslikethe ovaries, vitamin C may represent an excellent complement or alternative to hormone replacement therapy.

Not too long ago, it was believed that cardiac tissue was uniquely incapable of being regenerated. A new and rapidly growing body of experimental research now indicates that this is simply untrue. A class of heart-tissue regenerating compounds, known asneocardiogenicsubstances, are able to stimulate the formation of cardiac progenitor cells which can differentiate into healthy heart tissue. Neocardiogenicsubstances include the following:

Another remarkable example of cardiac cell regeneration is through what is known as the fetomaternal trafficking of stem cells through the placenta. The amazing process known as fetal microchimerism allows a fetus to contribute stem cells to the mother which are capable of regenerating her damaged heart cells, and possibly a wide range of other cell types.

Curcuminandresveratrolhave been shown to improve recovery from spinal cord injury. Over a dozen other natural compounds hold promise in this area, which can be viewed on GreenMedinfosspinal cord injurypage online. As far as degenerative joint disease, i.e. osteoarthritis, there are a broad range of potentially regenerative substances, with 50 listed on the sitesosteoarthritisresearch page.

Regenerative medicine poses a unique challenge to the current medical paradigm, which is based on costly drug trials, patents, and an economic infrastructure supported by drug-based interventions. It is a simple truth that symptom suppression is profitable. It guarantees both the perpetuation of the original underlying disease and the generation of an ever-expanding array of additional, treatment-induced symptoms known as side effects.

But cures, especially those that come from natural sources, dont have this built-in income potential. Worse perhaps, from a Big Pharma perspective, they can not be easily patented. In the current regulatory environment, that means that companies have no incentive to conduct the costly trials required to have these cures approved by the FDA and then used in clinical settings. Without patents, they cant be controlled and sold.

But suppressing symptoms with drugs that cause side effects requiring other drugs is a non-sustainable, infinite growth model. It is doomed to fail and eventually collapse.

The current approach also interferes with the bodys natural regenerative and immune capabilities. Cultivating diets, lifestyles and attitudes conducive to bodily regeneration can interrupt this pathological circuit. With true health, we can attain the bodily freedom that is a precondition for the liberation of the human spirit.

SayerJiis the founder ofGreenmedinfo.com, a reviewer at theInternational Journal of Human Nutrition and Functional Medicine, co-founder and CEO ofSystome Biomed, vice chairman of the board of theNational Health Federation, and steering committee member of theGlobal GMO Free Coalition.This article was originally published on GreenMedinfo.com

See the original post:
6 Bodily Tissues That Can Be Regenerated Through Nutrition - The Epoch Times

Read More...

The biggest threat to military readiness has nothing to do with combat – Business Insider

October 18th, 2019 3:45 am

While aging equipment and bureaucracy continue to put a strain on the military's performance, training injuries are also taking a devastating toll.

Soldiers injured during training missed more than 4 million duty days in the first half of 2019 alone, medical researchers said during a panel at the Association of the US Army's conference in Washington, D.C.

"Injuries are the number-one medical threat to readiness," preventative medicine researcher Dr. Bruce Jones said Wednesday. "Musculoskeletal injuries, due mostly to training and vigorous operational activities, are the biggest portion of that problem."

More than three out of four of these kinds of injuries are from overuse. Running accounted for 43% of training injuries, according to Jones, making it the leading cause. Work-related tasks, equipment maintenance, and similar activities were also significant contributors.

The US Army

Research also showed that the slower the runner, the more they risked injury. And while the Army has strict body mass index requirements for its soldiers, Jones' research found those who had middle to high BMIs had less chance of injury compared with those with lower BMIs.

"So it appears being somewhat overweight, but physically fit, is protective against musculoskeletal issues," Jones said.

High rates of training injury given the requirements put on the modern soldier might not be surprising, but the Army has established a network of Army Wellness Center locations in an effort to promote a healthier force. The centers test a soldier's body fat composition, caloric needs, and aerobic capacity in order to help them meet their fitness goals.

"Instead of going [with] the traditional health education, health promotion, what we wanted to do was something a little bit more evidence-based," said Todd Hoover, the Army Wellness Center operations division chief. "So instead of just like lecturing people, holding classes, and stuff like that, what we wanted to do was assess where they're at."

The Army could see more soldiers injured in training as it begins to implement its new fitness test, which aims to mirror the physical requirements expected in the field. The new dead lift, for example, could increase back injuries for soldiers unfamiliar with proper weightlifting techniques.

Jones told the Washington Examiner he suspects there could be more injuries associated with the new test, but it's too soon to tell.

"The bottom line is we will have to wait and see," he said.

See the rest here:
The biggest threat to military readiness has nothing to do with combat - Business Insider

Read More...

New Humana Study Suggests $1 out of $4 Spent on Healthcare Is Wasted Each Year – Citizen Truth

October 18th, 2019 3:45 am

(All Peer News articles are submitted by readers of Citizen Truth and do not reflect the views of CT. Peer News is a mixture of opinion, commentary and news. Articles are reviewed and must meet basic guidelines but CT does not guarantee the accuracy of statements made or arguments presented. We are proud to share your stories, share yours here.)Changing from reactive based healthcare to proactive based healthcare could help Americans save millions.

Humana released a study on Monday, October 7 revealing that $265 billion is being wasted on healthcare in the U.S. annually. With medical costs already at staggering highs, many Americans cant afford to waste money on unneeded healthcare. After all, as CNBC reports, rising health-care costs are a reality and cause stress for many peopleIf we are to successfully confront the issues of cost and efficiency in care, we first need to fully understand the systemic problem of wasteful spending.

The last thing anyone wants to worry about during a medical emergency or when facing a chronic condition is the cost of healthcare. Unfortunately, for many Americans, worrying about healthcare costs is a reality. After all, the U.S. spends more on healthcare than any other country. In order to waste less money, the healthcare system must evolve to deliver more cost-efficient care to each and every patient.

The ultimate goal of the study conducted by Humana and the University of Pittsburgh School of Medicine was to estimate the levels of monetary waste on healthcare in the U.S. They focused on the top six aspects of healthcare that are attributed to wasting money, including:

The study found that the administrative complexity is the greatest source of monetary waste. Administrative complexity involves physician credentials, information systems, processing of medical claims, and administrative operating. Patients expect these responsibilities to be carried out seamlessly, however, clinicians and health plans typically work separately which can contribute to waste.

Each of these domains of healthcare will require different kinds of action to eliminate waste while improving patients experiences.

Prior to this newly released study, various initiatives have been implemented to help mitigate healthcare spending. Some of these initiatives include payment reform (bundled payments, value-based arrangements/reimbursements) and delivery reform (enhanced care coordination, Partnership for Patients initiative). However, these initiatives have only made a minor dent in healthcare spending waste and substantial waste still remains.

Sadly, the authors of the study found no reputable studies that have effectively found ways to reduce administrative complexity. Very few value-based payment options have been able to produce sufficient savings.

Don Berwick, a renowned physician and author of an editorial examining the Humana study, suggests that moving to a single-payer system, simplifying administrative costs, and lowering branded drug prices could help reduce waste.

Additionally, the Affordable Care Act implemented an effective preventative care plan that providers can follow to lower costs and prevent wasted money by treating diseases such as mental illness, diabetes, multiple sclerosis, and many other chronic diseases.

Too often, people wait until symptoms become severe to seek medical care. This can contribute to higher healthcare costs and chronic conditions. This is known as the reactive care model. Focusing more on proactive and preventative care, however, can help drive down long term healthcare costs. Proactive healthcare involves targeted communication and improved engagement allowing patients to take control of their own health outcomes. In addition, proactive healthcare focuses on more collaboration among patients and physicians in small-scale practices to help lower administrative costs, therefore, preventing administrative complexity waste.

Reactive healthcare is responsible for more than 75% of healthcare spending. Proactive and preventative healthcare, on the other hand, focuses on preventing chronic disease and improving healthcare outcomes. As a result, conditions can be tackled at the root causes and treated before they become a dangerous problem that requires costly medical care.

Innovative types of healthcare that are focusing on proactive and preventative health include workplace wellness initiatives, age management programs, and concierge medicine. Advocates for changing healthcare using preventative and proactive medicine suggest that proactive medicine treats diseases before they become a bigger problem saving patients time and money in the long run.

Aside from preventing disease, proactive healthcare is also proven to increase retention rates and extend patients lifetime value. Retention is vital to keeping healthcare costs low, as it costs 5 to 25 times more to treat new patients than it does to retain old ones.

While preventative medicine may not be the end-all-be-all solution to wasted healthcare costs, it can certainly play a role in preventing disease in order to keep costs down. It is evident that further research and initiatives need to be done to improve the efficiency of administrative complexity and healthcare spending. Its safe to say that healthcare reform is critical to lowering costs and expanding healthcare access to all Americans in need without the excessive worry of wasted money.

View post:
New Humana Study Suggests $1 out of $4 Spent on Healthcare Is Wasted Each Year - Citizen Truth

Read More...

Nobel Econ winners ‘excited’ about their work – Yahoo News

October 18th, 2019 3:45 am

U.S.-based economists Abhijit Banerjee, Esther Duflo and Michael Kremer won the 2019 Nobel Economics Prize on Monday for work fighting poverty that has helped millions of children by favoring practical steps over theory.

French-American Duflo becomes only the second woman to win the economics prize in its 50-year history, as well as the youngest at 46. She shared the award equally with Indian-born American Banerjee and Kremer, also of the United States.

The Royal Swedish Academy of Sciences said their work had shown how poverty could be addressed by breaking it down into smaller and more precise questions in areas such as education and healthcare, and then testing solutions in the field.

It said the results of their studies and field experiments had ranged from helping millions of Indian schoolchildren with remedial tutoring to encouraging governments around the world to increase funding for preventative medicine.

"It starts from the idea that the poor are often reduced to caricatures and even the people that try to help them do not actually understand what are the deep roots of (their) problems," Duflo told reporters in Stockholm by telephone.

"What we try to do in our approach is to say, 'Look, let's try to unpack the problems one-by-one and address them as rigorously and scientifically as possible'," she added.

The team pioneered "randomized controlled trials," or RCTs, in economics. Long used in fields such as medicine, an RCT could for example take two groups of people and study what difference a treatment makes on one group while the other group is only given a placebo.

Applied to development economics, such field experiments found for example that providing more textbooks and free school meals had only small effects, while targeting help for weak students made a big difference to overall educational levels.

"It's a prize not just for us but for the whole movement," Banerjee later told a joint news conference at the Massachusetts Institute of Technology (MIT), where they both work. Kremer is a researcher at Harvard University.

Citing Banerjee's methods as having transformed classroom teaching in state schools in New Delhi, the Indian capital's chief minister Arvind Kejriwal said on Twitter that it was a "big day for every Indian."

Story continues

Continued here:
Nobel Econ winners 'excited' about their work - Yahoo News

Read More...

Semicon Europa to host Smart MedTech Forum in Munich – Med-Tech Innovation

October 18th, 2019 3:44 am

The Smart MedTech Forum atSemicon Europa will focus on innovation and the future of medtechat Messe Mnchen from 12-15 November.

The SMART MedTech Forum fosterscollaboration across the semiconductor and medtech value chains, and gathers industry experts for insights into the latest developments and trends in medtech innovations driven by semiconductors.

The Forum will be located at theInspiration Hub, an pavilion where attendees can connect with companies behind medtech innovations, experience leading products, and discover startups.

It features the following sessions focused on the critical role of semiconductors and medtech in enabling technology innovation and solutions to the worlds most pressing healthcare challenges.

Global healthcare solutions

Janssen Pharmaceutical Companies of Johnson & Johnson will hold a presentation on global healthcare challenges and opportunities, followed by MedTech Europe, which will discuss trends in healthcare, the medtech industry and digital. imec and GE Research will focus on bridging the gap between semiconductors and medical technologies to solve global healthcare challenges.

Digitisation of preventive healthcare

The focus of more Smart medtech device companies on preventive medicine sets the stage for a presentation by OnePlanet Connected Health Solutions on opportunities in digital health for tracking mental stress using wearable data and machine learning. Maxim Integrated will explore the potential of sleep monitoring to prevent health problems and reduce healthcare costs, and how wearables can help prevent high blood pressure. ams AG will examine how sensors can enable consumer health applications for preventative healthcare.

Revolutionising healthcare with personalised medicine

Personalised medicine is on the rise in its aim to increase the efficiency and quality of care through customised patient management. Yole Developpement and Fraunhofer EMFT will introduce innovative solutions in precision medicine and drug delivery for personalised healthcare, while X-FAB will discuss how MEMS manufacturing is enabling breakthroughs in personalised medicine.

The digital patient: The future of artificial organs and human avatars

Digital patients promise to prevent and cure disease and transform healthcare through personalised treatment. Key figures from EPFL Lausanne, Philips, Robert Bosch, and Bart's Heart Centre will discuss quantum leaps in personalised treatment including the use of artificial organs, Organ-on-Chip, and human avatars as the next paradigm in healthcare.

Pioneering research in medical technologies

With fundamental research key to healthcare innovation, research and innovation centres imec and the KU Leuven will explore how CMOS-compatible technologies and systems can be applied to life sciences to enable platforms for personalised medicine.

Other SMART MedTech Forum highlights

The Medtech Startup Session will host startups including Sensome and its remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. Onera Health and ChronoLife will introduce their diagnostic solutions, while PKvitality will present its health-monitoring smartwatches. ICAlps will present its products and services for the design and supply of ASIC/SOC integrated circuits for medtech applications.

Also, figures from ChronoLife, the European Commission and Siemens Healthineers will gather for the panel Key Drivers Transforming Healthcare: AI, Big Data and Cybersecurity, three areas central to medtech advances.

The rest is here:
Semicon Europa to host Smart MedTech Forum in Munich - Med-Tech Innovation

Read More...

Health clinic to return to University of Idaho campus – Argonaut

October 18th, 2019 3:44 am

The Vandal Health Clinic formerly known as the Student Health Clinic will move back to its Moscow campus location this fall.

The clinic was moved off campus last year to the downtown location of Moscow Family Medicine. It was moved again and is now located next to the QuickCare clinic behind WalMart.

We dont have a definitive date of being open, but itll be soon, Dean of Students Blaine Eckles said. Likely before Thanksgiving, if not sooner than that.

The on-campus clinic, located in the same building as the Student Health Insurance Office and Vandal Health Education, is in the final stages of being remodeled, Eckles said.

ICYMI: CTC fills psychiatry void

The clinic will house six exam rooms, a procedure room, office space for physicians and an x-ray room. It is unclear at this time if the clinic will have the capacity to do other types of lab work on site, but those resources will remain available through other healthcare facilities in Moscow.

There is room within the current space to expand.

The move (back to campus) was ultimately my decision, Eckles said. I dothat in consultation with campus leadership, the president. This conversation started last spring as an opportunity for us to engage. President Staben and Provost Wiencek were in support of that, President Green is in support of it as well.

The clinic was moved to the Gritman Medical Center location behind WalMart during the remodeling process because that location had the capacity to meet student needs better than the downtown Moscow Family Medicine location, Eckles said.

Moscow Family Medicine integrated with Gritman Medical Center last year, Eckles said, which allowed this move to happen.

Eckles said the team behind the move wanted to open the clinic sooner, but the remodel took time. It was originally predicted to open in January, but Eckles said the clinic is likely to open much sooner.

The physician who will be based out of the clinic, Dr. Jacob Christensen, completed a Primary Care Sports Medicine Fellowship at the University of New Mexico last summer and began seeing patients at the current clinic location recently.

Christensen will provide general healthcare in addition to mental, preventative and womens health services. He will also work with University of Idaho athletic teams as an athletic physician.

Eckles and Christiansen said there should not be any changes in services when the location of the clinic changes.

ICYMI: UI employees to expect higher rates for healthcare coverage

Some types of lab work may be unavailable on site, Christianson said, but finding alternatives and other local resources should not be a problem.

The Vandal Health Clinic will be open five days per week including over academic breaks and will be open to students, staff, faculty and other members of the campus community. Eckles said this will provide another line of healthcare service for students and ease access to services throughout Moscow, cutting down line sizes and wait times.

Eckles said he will send out a campus-wide email once a final opening date has been set for the clinic. The team plans to host a ribbon-cutting ceremony when the clinic opens.

Alexis Van Horn can be reached at arg-news@uidaho.edu or on Twitter @AlexisRVanHorn

Read more from the original source:
Health clinic to return to University of Idaho campus - Argonaut

Read More...

How to cheat death and save billions – TT Newsday

October 18th, 2019 3:44 am

Kiran Mathur Mohammed

kmmpub@gmail.com

The bodies and minds of half the country and more than $6.8 billion a year are being lost because we arent stopping heart disease, diabetes or mental illness before they kill us or lock us away.

How many of the men and women trapped in cages and defecating in buckets; that filled our screens last week, had treatable issues that might have been prevented much earlier?

You may not realise it, but we have more in common with those poor souls than we think.

You might not end up in a cage. But as dramatic will be the heart attack that suddenly robs you of life or health; or the innocuous doctors visit that turns into a gut wrenching revelation: Im sorry maam your eyesight is going, and possibly for good; Im sorry but your sons mania requires institutional confinement.

It is a natural human bias to discount early care and preventative treatment. Psychologists and economists alike fret about the reasons why we (and it is most all of us) dont spend enough time looking after our minds and our bodies.

Still, one in two people that die in this country die of heart disease, a stroke or diabetes, says the Health Ministry. And, says the World Health Organisation, in Latin America and the Caribbean up to 24.2 per cent of our populations suffer from some mental disorder ranging from anxiety to depression.

The equally wondrous and frustrating thing is that human knowledge and modern medicine make all these things largely preventable. We could literally glow with health.

How? Weve all been lectured about cutting out the refined starch, sugar, salt, and unhealthy fats. We all know we need to go for a walk or a hit the gym. We know we need to pop our pills. We all know we need to steer clear of smoking, cut down the booze and go see a shrink.

But its tough. The reality is that many unhealthy things like booze or ice-cream lubricate social interactions and enable experiences that bind us together with family, friends and strangers. And our culture still views soft feelings as a sign of weakness.

The concept that we must simply buckle down with self-discipline is old hat. We can only make the right choices if our whole lives are redesigned to help us do so.

We now know that a choice as simple as taking a heart pill is guided by a huge number of factors: from cost, to time, to physical access to education. Thats why more than 46 per cent of people dont even bother to fill their prescription, says Dr Mandreker Bahall.

The same goes for the decision to reach for broccoli instead of fried chicken. The Health Ministry reckons that 90 per cent of the population have less than five servings of fruit and vegetables daily, while 74.6 per cent of students still drink more than one sweet soft drink every day.

But changing these behaviours is not impossible.

First, we can throw more resources at capturing the crucial data that should inform our policymakers every decision, as UWI lecturer Dr Robin Seemongal-Dass and others have advocated.

Then we can quickly tack up a few whiteboards and map peoples decision processes from start to finish; from the decision to eat poorly, to the decision to not exercise or the decision to not take lifesaving medication. Once we find those pain points, we can surgically remove them.

Can technology make taking drugs less difficult or confusing? Can the State use school lunches to bombard children with vegetables? Can employers be convinced that physically active employees make them more money?

If spun right, a national preventative medicine programme, dull as it sounds could make as many headlines as announcing a new hospital. Look at the global attention New Zealands PM got with her mental health budget.

The opportunity is tremendous: dont forget the $6.8 billion that diabetes and heart disease extract through healthcare costs and lost productivity, as think-tank RTI International has measured.

The private health sector has just as much an incentive to get involved as the public. It is an opportunity for the health industry to enter the rapidly growing markets for wellness, and outpatient and continual care. GPs are the unsung heroes in this battle: people like Dr Maria Clapperton of the Caribbean Collection of Family Practitioners.

We must escape those dark places of last resort: the emergency room and the psychiatric ward. We still have the chance to cheat death.

Kiran Mathur Mohammed is a social entrepreneur, economist and businessman. He is a former banker, and a graduate of the University of Edinburgh

See the original post here:
How to cheat death and save billions - TT Newsday

Read More...

A Warning From a Doctor Who Has Done Thousands of Steroid Injections for Arthritis – The Atlantic

October 18th, 2019 3:44 am

As a specialist in joint pain, Guermazi has done thousands of steroid injections over decades of work. He has trained other doctors as he was trained: to believe that the injections are safe as long as they arent overused. But now he has come to believe that the procedure is more dangerous than he knew. And he and a group of his Boston University colleagues are raising a warning flag for doctors and patients alike.

Millions of times every year, people with joint pain allow doctors to run a needle through their skin, then their muscle, then their tendons, and into the fluid-filled space of a painful joint to calm inflammation. Such inflammation can be the result of many types of injury or disease, but most commonly it is the result of gradual wear and tear known as osteoarthritis, in which the cartilage diminishes, the space between the bones narrows, and eventually bones start to rub on one another. At that stage, a person may need a surgical joint replacement. The progression of the disease itself cant be reversed with drugs, so medical treatment is aimed at easing pain and maximizing mobility. Steroid injections are one of the chief ways this is attempted.

In the journal Radiology this week, Guermazi and his colleagues at Boston University published a study of 459 patients at their hospital who got injections, in the hips or knees, in 2018. Of those patients, 8 percent had complications that worsened the state of their joints. In some cases, the arthritis actually sped up. Others developed small fractures under the cartilage or had complications that compromised the blood supply to bone. In the worst cases, patients had what Guermazi and his colleagues described as rapid joint destruction.

Patterns of harm can be slow to emerge in medicine, and causal relationships are difficult to prove. But these findings build on a gradual accretion of evidence challenging the widespread use of steroid injections. In 2015, Cochrane Musculoskeletal did a meta-analysis to see if the intervention was even helpful. After collating data from 27 knee-arthritis trials carried out around the world, the authors concluded that the quality of evidence was low and overall inconclusive. Some of the studies they analyzed found small to moderate improvements in pain and physical function, but the results were not statistically reliable. Whether there is truly any positive effect, the authors concluded, is unclear.

Since then, the role of the placebo effect in steroid injections has gotten attention. In 2017, rheumatologists at Tufts University and Boston University did a randomized controlled trial in people with knee pain. A control group got a sham injection that contained no steroids. In what became a bombshell paper in the journal JAMA, people with knee arthritis reported that their pain was no different if they received injections of steroids or saline. Whats more, the people who got the steroid injections saw more erosion in the cartilage in their knees.

Here is the original post:
A Warning From a Doctor Who Has Done Thousands of Steroid Injections for Arthritis - The Atlantic

Read More...

Liver Fibrosis, Stiffness Rates in Rheumatoid Arthritis and Methotrexate Therapy – Rheumatology Advisor

October 18th, 2019 3:44 am

Although liver fibrosis and liver stiffness are more common in patients with rheumatoid arthritis (RA) compared with the general population, methotrexate (MTX) treatment does not appear to be a contributing factor, according to research published in the European Journal of Internal Medicine.

Using data from consecutive patients with RA, researchers sought to determine the role of MTX therapy in the development of liver stiffness and liver fibrosis. Categorically, patients who were MTX-nave and MTX-treated were assessed via real-time 2-dimensional shear wave elastography technology (2D.SWE.SSI).

The total cohort included 140 MTX-treated, 33 MTX-nave, and 100 healthy controls with a similar mean age and gender distribution across all groups. However, MTX-nave patients had a significantly shorter disease duration and higher Health Assessment Questionnaire compared with patients who were treated with MTX. In the MTX-treated group, the mean cumulative dose of MTX was 37153560 mg, with a mean time of treatment exposure of 71.366.4 months.

Liver stiffness (kPa) values were significantly lower in healthy controls compared with both patients who were MTX-nave and MTX-treated (4.320.7 vs 4.920.8 and 4.850.9, respectively). The difference in kPA values between the 2 MTX groups was not statistically significant.

Researchers, through the results of a multiple linear regression analysis, found that RA diagnosis, older age, and being a man were independently associated with higher liver stiffness values. An additional multiple linear regression analysis found that increasing age and being a man, but not treatment with and cumulative dose of MTX, were independently associated with increasing liver stiffness in patients with RA.

Based on a proposed cutoff of 7.1 kPa, only 4 out of 173 patients with RA were classified as having significant liver fibrosis (kPa values range 7.1-7.6). All 4 of these patients were in the MTX-treated RA group. However, these patients did not have liver function abnormalities or clinical signs of hepatic failure.

One study limitation is the lack of histological confirmation of hepatic fibrosis, which researchers note would have been difficult to justify from an ethical point of view. Additional limitations include the possibility of selection bias and the cross-sectional nature of the study design.

Significant liver fibrosis and liver stiffness in RA patients appear to be independent of MTX use, the researchers concluded. [The] 2D.SWE.SSI technique could be a promising tool to assess the severity of and to follow-up liver stiffness in RA patients and other chronic inflammatory conditions under MTX treatment.

Reference

Erre GL, Cadoni ML, Meloni P, et al. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: a cross-sectional controlled study with real-time two-dimensional shear wave elastography [published online August 29, 2019]. Eur J Intern Med. doi: 10.1016/j.ejim.2019.08.022

The rest is here:
Liver Fibrosis, Stiffness Rates in Rheumatoid Arthritis and Methotrexate Therapy - Rheumatology Advisor

Read More...

Claire King health: Emmerdale star’s diagnosis I was shocked and devastated’ – Express

October 18th, 2019 3:44 am

Claire King, 57, has played the role of Kim Tate in ITVs Emmerdale since 1989. The actress has been open about her almost 30-year battle with rheumatoid arthritis. Rheumatoid arthritis is a long-term condition that causes painful joints, as well as stiffness and swelling. The condition is something her mother Angela also has. Speaking to Mail Online in 2017, Claire revealed: I was shocked and devastated when I was diagnosed with arthritis at 30. You presume it's an older person's disease. Nowadays, I have had to give up bombing round on a race horse at 40 miles an hour but I still go for a hack. It doesnt hold me back, its manageable. Youve just got to get on with it.

The former Coronation Street star has feared the painful, chronic disease would leave her wheelchair-bound when she was first diagnosed.

The actress was told about her condition after going to the doctors with throbbing and painful fingers.

A blood test later revealed and confirmed her condition of rheumatoid arthritis

But thankfully with exercise, supplements and eating healthy, Claire has managed to keep the symptoms minimal and manageable.

Claire revealed that she is taking natural treatments and supplements thanks to her brothers recommendation.

She revealed she takes omega 3 which is a supplement that has demonstrated its ability to improve symptoms in a number of studies.

Claire who said she finds the winter months harder in terms of pain was put on hydroxychloroquine sulphate to suppress her immune system at 38 as well as meloxicam, an anti-inflammatory.

She also takes B vitamins, including vitamin B12, as it reduces homocysteine, an amino acid found in high levels in people with rheumatoid arthritis which increases pain and inflammation.

When it comes to eating for her condition, Claire said: Its must common sense, I eat healthy stuff, as unprocessed as possible.

"Keeping your weight in check is important when you have arthritis. I make sure I get enough iron, so plenty of spinach and green veg.

"There is a link between anaemia, low red blood cell levels, and rheumatoid arthritis.

"Iron helps prevent this by helping produce haemoglobin, the protein in red blood cells that carries oxygen throughout the body.

Exercising is also crucial for arthritis as it helps ease pain and stiffness.

It also increases the strength and flexibility, reducing joint pain and helping to combat fatigue.

I love walking, I live in the Dales so I'm out hiking every weekend.

"I'm lucky enough to have a second home in Spain with a pool so when I'm there I'm swimming every day.

"I do some stretching without fail every morning too which sets me up to feel better for the rest of the day.

"Exercise helps keep the joints mobile and just doing a little of what you can manage and what you enjoy can make a difference long-term, added Claire.

Link:
Claire King health: Emmerdale star's diagnosis I was shocked and devastated' - Express

Read More...

Hobbies Help Me Cope with the Mental Challenges of Juvenile Arthritis – Juvenile Arthritis News

October 18th, 2019 3:44 am

Everyone, from family members to strangers on the subway, knows that I love to crochet. Its rare to find me without my lightweight, ergonomic hooks and a ball of yarn. This year, I completed seven shawls, four scarves, two purses, and one big blanket. I hope to finish more projects in time for Christmas.

For me, crocheting and other forms of art are much more than merely a way to pass the time. Theyve improved my quality of life since I grew up with juvenile arthritis (JA). Throughout my childhood and teenage years, I spent hours drawing or crafting while lying on the couch. My art served as both distraction therapy and a way to keep busy when I wasnt well enough to go out to play with friends.

Reflecting on my dedication to my crafts over the years, I realize its been more than a physical coping method. My hobbies also help me to deal with the emotional burden of JA. Engaging in activities that I enjoy offers me hope, benefits my mental health, and gives me an identity apart from my disease.

Hope is a powerful thing that can inspire us to work hard to achieve a goal and to maintain a positive outlook during dark times.

Ive had flares that knocked me down for days or weeks at a time. I may not have been up to crafting then, but my next project was never far from my thoughts. I would scroll through Pinterest, longing to follow the tutorials that appeared in my feed. Looking at boards full of new projects made me eager to recover. I found it easier to stick to medication and physical therapy routines when I had something to look forward to.

As I recovered from flares, I often pushed myself to work on my projects. I would start slowly, with 15-minute stretches, before building up to longer sessions. Spending time crafting and drawing helped to keep my spirits up and was probably good physical therapy, too.

Id be lying if I told you that Ive never struggled with depression. I had some dark times, particularly in my teens. Living with chronic pain made me feel isolated from others, and my usual activities, including art, became unappealing to me.

I didnt start feeling better until things changed in my life, including the introduction of a new medication regimen and counseling. I also credit my improved mental health to taking art classes. Learning how to draw improved my self-esteem, gave me confidence, and brought joy into my life. The first drawings in my sketchbook were somber, black-and-white portraits. But by the time I graduated from the course, my portfolio was filled with colorful paintings of fluffy animals, babies, and musicians. I also made a lifelong friend through the class.

Of course, hobbies are nota cure for depression or anxiety. No amount of wreath-making or crocheting can take away negative feelings. But yarn crafts, painting, and other forms of self-expression are used by therapists to help those suffering from mental health problems.

Juvenile-onset arthritis has affected me every day since childhood. While Ive learned to cope with chronic pain, the disease still affects many aspects of my daily life. Some days, its hard for me to remember that having arthritis is not who I am its just something I have.

My blog and social media accounts may be titled, The Girl with Arthritis, but Im glad that the people in my life dont call me that. My family and friends call me the artist. More recently, Ive been the girl who crochets pretty shawls and the baker. Taking pride in my favorite activities and sharing them with others have helped me to create an identity separate from JA.

Parents: Encourage your child to pursue an activity they show interest in. I genuinely believe that anyone with a chronic disease can benefit from participating in a hobby they love. While crafting happens to be my favorite thing to do, the possibilities are endless.

My friends write stories and poetry, learn computer coding, make music, scrapbook, create comics, and even play the board game Dungeons & Dragons. Find something that brings joy to your life and adapt it to suit your needs. Your child might find a supportive community through classes or clubs. Youll never know until you encourage them to follow their passions.

***

Note: Juvenile Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Juvenile Arthritis News, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to juvenile arthritis.

Elizabeth Medeiros is a young adult who has dealt with juvenile arthritis since she was a small child. However, her pain hasnt stopped her from working on a product design degree in Boston. Her passion is to create products that make life easier for the chronically ill, such as shoes and walking canes. When shes not in class, Elizabeth enjoys writing about how shes coped with arthritis at such a young age. You can find more of her writings at ArthritisGirl.Blogspot.com and on Instagram @GirlWithArthritis.

The rest is here:
Hobbies Help Me Cope with the Mental Challenges of Juvenile Arthritis - Juvenile Arthritis News

Read More...

Some days its debilitating: When joint pain takes over your life – Global News

October 18th, 2019 3:43 am

Justin Furman can no longer go for long walks along the beach.

The 30-year-old Toronto man says that during his honeymoon in Zanzibar this past summer, even something as simple as walking would hurt his knees.

Ive been dealing with [the pain] for a decade now. My wife is used to [and] sympathetic to the issue at this point, he told Global News. Its frustrating.

READ MORE: A quiet epidemic Why so many Canadians experience knee pain

Furman, like many Canadians, deals with joint pain, a problem he said started after a series of football injuries years prior.

I played until I tore my hamstring about three-quarters of the way, he continued. Now the pain is predominantly in my right knee It just feels unstable.

David Wilson, professor of orthopedics and co-director of the Centre for Hip Health and Mobility at the University of British Columbia and Vancouver Coastal Health Research Institute, tells Global News the two common causes of joint pain are injury and arthritis.

Story continues below advertisement

The most common type of arthritis is osteoarthritis, which involves degeneration of the joint tissues like cartilage and bone, he explained. People are at higher risk of osteoarthritis if they have injured their joints, are overweight, or have an occupation that puts a lot of repetitive load on the joint.

About six million Canadians have arthritis thats one in every five people and nearly 60 per cent of people with arthritis are women, according to the Arthritis Society.

The prevalence of arthritis is on the rise by 2040, 50 per cent more people will have arthritis, the organization says. People with arthritis are more likely to experience anxiety, mood disorders, poor mental health, and difficulty sleeping, compared to those without arthritis.

Arthritis can be tricky because it can be hard for some to recognize when normal aches and pains of older joints turn into osteoarthritis.

Osteoarthritis is a slow-moving disease, Wilson explained. In the hip, in particular, the symptoms can come and go as well.

Many people are surprised to be diagnosed with osteoarthritis, especially if they are in their 30s or 40s, he noted.

However, there are more and more cases of osteoarthritis in these younger age groups, he said. A diagnosis of osteoarthritis can make a young person feel old, but it is the first step to coming up with a plan for managing or treating joint pain caused by this disease.

Story continues below advertisement

Anna Weigt-Bienzle of Toronto was diagnosed with rheumatoid arthritis at the age of 22.

She tells Global News almost all of her joints were impacted.

Its also a symmetrical disease, so if my right wrist joint is hurting, the left is likely to be affected as well.

Some days its debilitating and others I hardly notice it. Mornings can be challenging since thats when I tend to experience the most stiffness in my joints, so I try to wake up a littler earlier to give my body extra time.

And when you have a condition like rheumatoid arthritis, so much of your everyday life begins to change.

Having to go to work for the first time with my cane at 26 was a definite hit to my pride, she continued.

Ive had a flare-up on a date where my TMJ [the joint that connects the jaw to the skull] was inflamed and I could hardly open my mouth, which made eating nearly impossible, not to mention an end-of-night kiss.

Another time, Weigt-Bienzle had a flare-up in her knee during a party in an apartment without an elevator. A friend had to carry her down the stairs.

She says coming to a proper diagnosis took two years.

I was bounced around between several doctors and given various diagnoses, including lupus, Parkinsons and MS before they were able to figure out it was rheumatoid arthritis.

Story continues below advertisement

Besides taking medication, she also practises yoga three times a week to manage the pain.

I make sure to walk frequently and utilize my standing desk intermittently at work, she explained. With joint pain it can be challenging to move at times, but the longer you stay still, the worse it is.

Wilson says as soon as you feel any type of pain, talk to your family doctor.

They are best equipped to assess the cause of pain, understand your specific health situation and where joint pain fits in, and recommend how to manage it, he said. If the pain is from osteoarthritis, there are effective treatment options, including physical therapy, weight loss, medication and joint replacement.

Furman says he went to see a doctor as soon the pain started. He had several MRIs and was told he had a torn meniscus.

I was instructed to deal with the pain as long as I could.

In the meantime, he manages his pain with off-the-counter drugs like Advil and Robaxacet.

Generally, just have to give the knees a rest every so often, he said.

Story continues below advertisement

READ MORE: It was like getting my life back New knee replacement protocol helps patients go home sooner

Before you take any type of medication, Wilson says talk to your doctor first.

If you have osteoarthritis, you will likely have to manage it for years, and a doctor should be part of all decisions on long-term use of any medication, he said.

Some prescription medications are designed to reduce the side-effects that become a concern with long-term use of pain medication.

He adds that people can also discuss natural remedies and supplements with their doctors. Many of the claims made for them are optimistic and unsubstantiated by solid research.

Exercise can also be helpful.

READ MORE: How arthritis sufferers can reduce inflammation through food

There is a structured osteoarthritis education and exercise program that has been rolled out in five provinces called GLA:D, Wilson said.

GLA:D has been shown, he adds, to reduce pain and increase physical activity.

Best of all, exercise doesnt have the risks of medication and surgery.

Story continues below advertisement

2019 Global News, a division of Corus Entertainment Inc.

Excerpt from:
Some days its debilitating: When joint pain takes over your life - Global News

Read More...

Coronary Artery Disease in Adults with History of Juvenile Arthritis – DocWire News

October 18th, 2019 3:43 am

OBJECTIVE:

To define the risk of coronary artery disease (CAD) in adults with a history ofjuvenile arthritis(JA) METHODS: We used the National Health and Nutrition Examination 2007-2014 Surveys. Two comparison groups were identified: 1) random sample withoutarthritis, and 2) respondents with reported rheumatoidarthritis(RA). Coronary artery disease was defined as yes to survey questions: Have you ever been told you had congestive heart failure, coronary heart disease, angina/angina pectoris, heart attack, or stroke? Potential confounders for CAD included age, gender, race, smoking status, and any component of metabolic syndrome.

There were 232 respondents who reported JA; 1,028 randomly selected withoutarthritis; and 1,105 who reported RA. In simple logistic regression, the JA group had a three -fold increased odds of CAD compared to those withoutarthritis(odds ratio (OR): 3.2, 95% confidence interval (CI): 2.1-4.8, p<0.0001). Controlling for confounders, the odds of CAD in JA continued to be increased (OR: 4.2, 95% CI: 4.7-10.5, p=0.002). When comparing the JA and RA groups, in simple logistic regression, the JA group had a lower odds of CAD (OR 0.7, 95% CI: 0.5-0.9, p=0.03). Controlling for confounders, there was no significant difference in odds of CAD between groups (OR 0.8, 95% CI: 0.5-1.3, p=0.4).

Adults with a history of JA have a higher risk of CAD compared to adults withoutarthritis. Providers should be aware of the increased risk of CAD in adults withjuvenile arthritisand aggressively screen these patients for modifiable risk factors.

See the original post:
Coronary Artery Disease in Adults with History of Juvenile Arthritis - DocWire News

Read More...

The Prognostic Importance of EVI1 Expression – Cancer Network

October 18th, 2019 3:41 am

In AML, the role of ecotropic virus integration site-1 (EVI1) expression is debated. To date, results of studies have been mixed with only some studies demonstrating EVI1 expression related to poorer survival. In a meta-analysis published in the Annals of Hematology, researchers set out to uncover the predictive capability of this marker.

As a malignant disorder in hematology usually with a poor prognosis, AML needs an accurate prediction of prognosis to indicate protocoling the appropriate therapy regimens for patients hoping for survival improvement, wrote authors, led by Xia Wu, Department of Hematology, West China Hospital, Sichuan University, Sichuan Province. Molecular markers increasingly play an utmost significant role in the diagnosis and risk stratification of AML.

In the current meta-analysis, Wu et al. mined 11 studies for 4767 AML patients with intermediate cytogenetic risk (ICR), according to National Comprehensive Cancer Network (NCCN), International System for Human Cytogenetic Nomenclature (ISCN), or European leukemia network (ELN) guidance. The findings indicated that EVI1 expression negatively impacted OS (HR = 1.73, 95%CI 1.432.11) and event=free survival or EFS (HR = 1.17, 95%CI 1.051.31). Furthermore, EVI1 was a negative predictor of prognosis in patients with normal cytogenetics (NC) and younger patients (< 60 years).

Importantly, the investigators noted that due to location, altered EVI1 most often accompanies 3q26 rearrangements. However, it remains to be elucidated whether increased EVI1 expression is related to AML outcomes in those without 3q mutations. On a related note, higher levels of EVI1 may affect AML subgroups differently, which, according to the authors, is of utmost significance for clinical physicians.

In other findings, EVI1H expression was rarely found with NPM1, FLT3-ITD and DNMT3A mutations. Wu et al point to these mutations and mutations as avenues of further research.EVI1 is a transcription factor on chromosome 3. It was first discovered two decades ago in murine models. It has stem cell specific expression patterns and mediates growth of hematopoietic stem cells, and plays a role in AML, myelodysplastic syndrome (MDS), and CML.

The investigators suggested that the findings of the current study could assist clinicians with risk stratification and treatment decisionsespecially because most patients are NC.

EVI1, which also goes by MECOM, encodes a 145 kDa-unique zinc finger that attaches with DNA. This transcription factor is hypothesized to interfere with granulocyte and erythroid cell differentiation, as well as promotion of megakaryocyte breakdown, to aid with the differentiation and proliferation of hematopoetic stem cells.Several drug targets for EVI1 have been suggested such those involved in leukemogenesis and stem cell maintenance. Examples include the transcription factor Pre-B Cell leukemia Homeobox 1 (PBX1) and Phosphatase and Tensin Homolog (PTEN), which is a tumor suppressor gene. However, none of these targets have proven related to EVI1-deregulated AML.

Per the authors the current study had several limitations. First, most studies in the meta-analysis were observational and not randomized-controlled trials. Second, the sample contained cases of therapy-related AML and secondary AML, which have a worse prognosis and could thus confound results. Third, limited OS data precluded the ability to study AML patients without 3q alterations. Fourth, the studies were highly heterogeneous in a clinical sense.

Reference

Wu X et al. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Annals of Hematology. 2019 Sep 3. doi: 10.1007/s00277-019-03774-z.

Read this article:
The Prognostic Importance of EVI1 Expression - Cancer Network

Read More...

Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes – BioSpace

October 18th, 2019 3:41 am

Findings further validate Cell Pouch and therapeutic cell performance in Type-1 diabetes

LONDON, ONTARIO October 16, 2019 Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine company, is pleased to announce the detection of enduring levels of C-peptide (measured up to 30 days and ongoing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its ongoing Phase I/II Cell Pouch(TM) US clinical study of type-1 diabetes. The detection of fasting C-peptide in the bloodstream of our first patient, in addition to Sernovas recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the bodys varied need for insulin production. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch.

Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patients bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernovas Cell Pouch, said Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. We look forward to reporting ongoing results in additional patients as the trial progresses.

The entry criteria of Sernovas clinical study require patients to be C-peptide negative upon enrolment. C- peptide measured in the bloodstream is a biomarker of insulin and is widely used as a measure of insulin production by islet cells. C-peptide is typically measured following overnight fasting (fasting C-peptide) and during a glucose tolerance test (glucose-stimulated C-peptide). Together these measures provide an index of the patients ability to control blood glucose through their production of insulin.

With the goal of improved blood glucose control and stabilization of fluctuating blood sugar levels commonly experienced in people with type-1 diabetes, a normalizing response can also decrease the likelihood of life threatening hypoglycemic unaware events, a key efficacy measure in the Sernova trial.

Sernovas clinical trial is continuing active recruitment and enrollment of study participants and further results will continue to be reported as the study progresses.

ABOUT SERNOVAS CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the companys patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Importantly, patients enrolled in Sernovas clinical trial are incapable of producing C- peptide prior to implantation of Sernovas Cell Pouch and therapeutic cells.

Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit http://www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit http://www.pwitkowski.org/sernova.

ABOUT SERNOVAS CELL POUCH

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com

Read more here:
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes - BioSpace

Read More...

InvestmentPitch Media Video Discusses Sernova Corp’s Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes – Video…

October 18th, 2019 3:41 am

Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, has reported findings that further validate Cell Pouch and therapeutic cell performance in Type-1 diabetes. The Cell Pouch is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets.

InvestmentPitch Media has produced a "video" which describes this news. If this link is not enabled, please visit http://www.InvestmentPitch.com and enter "Sernova" in the search box.

Cannot view this video? Visit:http://www.investmentpitch.com/

The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

Sernova reported the detection of enduring levels of C-peptide, measured up to 30 days and ongoing, in the bloodstream of a fasting patient in its ongoing Phase I/II Cell Pouch US clinical study of type-1 diabetes. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch, as patients enrolled in Sernova's clinical trial have been incapable of producing C-peptide, prior to implantation of Sernova's Cell Pouch and therapeutic cells.

Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator, stated: "Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient's bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova's Cell Pouch. We look forward to reporting ongoing results in additional patients as the trial progresses."

The entry criteria of Sernova's clinical study require patients to be C-peptide negative upon enrolment. C-peptide, a biomarker of insulin and widely used as a measure of insulin production by islet cells, is typically measured following overnight fasting and during a glucose tolerance test. Together these measures provide an index of the patient's ability to control blood glucose through their production of insulin.

With the goal of improved blood glucose control and stabilization of fluctuating blood sugar levels commonly experienced in people with type-1 diabetes, a normalizing response can also decrease the likelihood of life threatening hypoglycemic unaware events, a key efficacy measure in the Sernova trial.

Sernova's clinical trial is continuing active recruitment and enrollment of study participants and further results will continue to be reported as the study progresses.

For more information on this clinical trial, please visit http://www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit http://www.pwitkowski.org/sernova.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells, such as human donor cells, corrected human cells and stem-cell derived cells, to improve the treatment and quality of life of people with chronic metabolic diseases. These diseases include insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

For more information, please visit the company's website http://www.sernova.com, contact Dominic Gray, Corporate Communications, at 519-858-5126 or email dominic.gray@sernova.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news, research reports and other content of interest to its following of retail, institutional and accredited investors.

Story continues

Original post:
InvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video...

Read More...

Page 871«..1020..870871872873..880890..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick